Having clinical trials hosted at DF/HCC should place Cellceutix at the forefront of developmental biotechs of all sizes, regardless of exchange listing; especially those in Phase I and a good portion of those in Phase II at lesser-known cancer centers. While no hospital ensures a positive outcome to clinicals, it could be discerned that odds are increased due to the selective nature of compounds that are permitted to enter trials at DF/HCC.

Moreover, due to Kevetrin™ targeting drug-resistant cancers, Cellceutix will be researching their drug on terminal cancer patients (their ideal candidate) which raises the bar during Phase I as not only will the primary endpoint of safety be evaluated, but the possibility of efficacy being shown is a reality of the trials. Any sign of efficacy for a completely novel compound significantly increases the odds of expeditious development designations from the FDA.